⌘K

/

/

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

モデル
薬剤
インサイト

Company

CROパートナー
Contact Us
Privacy Policy

© 2025 Fibrosis-Inflammation Lab. All rights reserved.

Privacy Policy Terms of Service

Lanifibranor (Lanifibranor) | 加速させる、線維化研究を

Home/Drugs/Lanifibranor

Lanifibranor

Lanifibranor

Phase 3

Sponsor: Inventiva

Indication: MASH

Mechanism of Action

Pan-PPAR Agonist

Target: PPAR-alphaTarget: PPAR-deltaTarget: PPAR-gamma

Clinical Information

Approval Year

Clinical Trials (ClinicalTrials.gov)

COMPLETEDNCT06126562

A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects

Phase:PHASE1Org:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

COMPLETED

Relevant Publications (PubMed)

No recent publications found for Lanifibranor.

Validated Models

This drug has been validated in the following preclinical models:

NCT05232071

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT03459079

Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease

Phase:PHASE2Org:University of Florida

COMPLETEDNCT03008070

Phase 2b Study in NASH to Assess IVA337

Phase:PHASE2Org:Inventiva Pharma

COMPLETEDNCT03866369

Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose

Phase:PHASE1Org:Inventiva Pharma

View all trials on ClinicalTrials.gov